Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00063141
Other study ID # CA225-006
Secondary ID
Status Completed
Phase Phase 3
First received June 20, 2003
Last updated April 8, 2010
Start date April 2003
Est. completion date October 2007

Study information

Verified date April 2010
Source ImClone LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.


Other known NCT identifiers
  • NCT00065598

Recruitment information / eligibility

Status Completed
Enrollment 1302
Est. completion date October 2007
Est. primary completion date June 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically documented colorectal cancer which is EGFR-positive by immunohistochemistry [IHC] (may be based on archival samples) and is metastatic.

- Prior oxaliplatin administered for the first-line treatment of metastatic colorectal cancer.

- Prior fluoropyrimidine-containing regimen (5-fluorouracil [5-FU], capecitabine, or uracil/tegafur [UFT]), for the first-line treatment of metastatic disease.

Exclusion Criteria:

- A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy

- Unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease

- Known or documented brain metastases

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
cetuximab
Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
Irinotecan
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Irinotecan
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Locations

Country Name City State
Australia ImClone Investigational Site Adelaide South Australia
Australia ImClone Investigational Site Perth Australian Capital Territory
Australia ImClone Investigational Site South Brisbane Queensland
Australia ImClone Investigational Site Sydney Australian Capital Territory
Australia ImClone Investigational Site Sydney New South Wales
Australia ImClone Investigational Site Wien
Australia ImClone Investigational Site Wollongong New South Wales
Austria ImClone Investigational Site Graz
Austria ImClone Investigational Site Salzburg
Austria ImClone Investigational Site Wein
Austria ImClone Investigational Site Wien
Belgium ImClone Investigational Site Charleroi
Czech Republic ImClone Investigational Site Brno
Czech Republic ImClone Investigational Site Olomouc
Czech Republic ImClone Investigational Site Praha 5
Finland ImClone Investigational Site Helsinki
France ImClone Investigational Site Avignon
France ImClone Investigational Site Marseille
France ImClone Investigational Site Nice
France ImClone Investigational Site Saint Herblain
Germany ImClone Investigational Site Aschaffenburg
Germany ImClone Investigational Site Augsburg
Germany ImClone Investigational Site Dessau
Germany ImClone Investigational Site Dortmund
Germany ImClone Investigational Site Essen
Germany ImClone Investigational Site Hamburg
Germany ImClone Investigational Site Hanburg
Germany ImClone Investigational Site Kaiserslautern
Germany ImClone Investigational Site Kassel
Germany ImClone Investigational Site Magdeburg
Germany ImClone Investigational Site Mainz
Germany ImClone Investigational Site Mannheim
Germany ImClone Investigational Site Muchnhen
Germany ImClone Investigational Site Munchen
Germany ImClone Investigational Site Regensburg
Germany ImClone Investigational Site Saarbrucken
Germany ImClone Investigational Site Stralsund
Germany ImClone Investigational Site Stuttgart
Hong Kong ImClone Investigational Site Hong Kong
Italy ImClone Investigational Site Ancona
Italy ImClone Investigational Site Bergamo
Italy ImClone Investigational Site Candiolo
Italy ImClone Investigational Site Firenze
Italy ImClone Investigational Site Genova
Italy ImClone Investigational Site Livomo
Italy ImClone Investigational Site Milano
Italy ImClone Investigational Site Modena
Italy ImClone Investigational Site Napoli
Italy ImClone Investigational Site Perugia
Italy ImClone Investigational Site Reggio Emilia
Italy ImClone Investigational Site Roma
Italy ImClone Investigational Site Rome
Italy ImClone Investigational Site Rozzano Milano
Netherlands ImClone Investigational Site Apeldorn
Netherlands ImClone Investigational Site Dordrecht
Norway ImClone Investigational Site Montebello Oslo
Norway ImClone Investigational Site Oslo
Portugal ImClone Investigational Site Porto
Slovakia ImClone Investigational Site Bratislava
Sweden ImClone Investigational Site Lund
Sweden ImClone Investigational Site Stockholm
Switzerland ImClone Investigational Site Bern
Switzerland ImClone Investigational Site Liestal
Switzerland ImClone Investigational Site Zurich
United Kingdom ImClone Investigational Site Bournemouth Hampshire
United Kingdom ImClone Investigational Site Foresterhill Aberdeenshire
United Kingdom ImClone Investigational Site Glasgow Central
United Kingdom ImClone Investigational Site Guildford Surrey
United Kingdom ImClone Investigational Site Hull Avon
United Kingdom ImClone Investigational Site London Greater London
United Kingdom ImClone Investigational Site Poole Dorset
United Kingdom ImClone Investigational Site Sutton Surrey
United States ImClone Investigational Site Albany New York
United States ImClone Investigational Site Ann Arbor Michigan
United States ImClone Investigational Site Arlington Virginia
United States ImClone Investigational Site Atlanta Georgia
United States ImClone Investigational Site Atlanta Georgia
United States ImClone Investigational Site Aurora Colorado
United States ImClone Investigational Site Austin Texas
United States ImClone Investigational Site Bakersfield California
United States ImClone Investigational Site Baltimore Maryland
United States ImClone Investigational Site Baton Rouge Louisiana
United States ImClone Investigational Site Berkeley California
United States ImClone Investigational Site Beverly Hills California
United States ImClone Investigational Site Bismarck North Dakota
United States ImClone Investigational Site Boston Massachusetts
United States ImClone Investigational Site Bronx New York
United States ImClone Investigational Site Cincinnati Ohio
United States ImClone Investigational Site Cleveland Ohio
United States ImClone Investigational Site Columbus Ohio
United States ImClone Investigational Site Columbus Georgia
United States ImClone Investigational Site Corona California
United States ImClone Investigational Site Dallas Texas
United States ImClone Investigational Site Danville Virginia
United States ImClone Investigational Site Dayton Ohio
United States ImClone Investigational Site Denver Colorado
United States ImClone Investigational Site Detroit Michigan
United States ImClone Investigational Site Durham North Carolina
United States ImClone Investigational Site East Setauket New York
United States ImClone Investigational Site Fort Myers Florida
United States ImClone Investigational Site Fort Myers Florida
United States ImClone Investigational Site Frederick Maryland
United States ImClone Investigational Site Gilroy California
United States ImClone Investigational Site Green Bay Wisconsin
United States ImClone Investigational Site Greenbrae California
United States ImClone Investigational Site Greenville North Carolina
United States ImClone Investigational Site Greenville South Carolina
United States ImClone Investigational Site Hershey Pennsylvania
United States ImClone Investigational Site High Point North Carolina
United States ImClone Investigational Site Honolulu Hawaii
United States ImClone Investigational Site Houston Texas
United States ImClone Investigational Site Inverness Florida
United States ImClone Investigational Site Jackson Mississippi
United States ImClone Investigational Site Jacksonville Florida
United States ImClone Investigational Site Jacksonville Florida
United States ImClone Investigational Site Jacksonville Florida
United States ImClone Investigational Site Kansas City Missouri
United States ImClone Investigational Site Kansas City Kansas
United States ImClone Investigational Site Knoxville Tennessee
United States ImClone Investigational Site Lafayette Louisiana
United States ImClone Investigational Site Lakeland Florida
United States ImClone Investigational Site Latham New York
United States ImClone Investigational Site Lexington Kentucky
United States ImClone Investigational Site Long Beach California
United States ImClone Investigational Site Los Angeles California
United States ImClone Investigational Site Los Angeles California
United States ImClone Investigational Site Louisville Kentucky
United States ImClone Investigational Site Macon Georgia
United States ImClone Investigational Site Madison Wisconsin
United States ImClone Investigational Site Memphis Tennessee
United States ImClone Investigational Site Metairie Louisiana
United States ImClone Investigational Site Miami Florida
United States ImClone Investigational Site Milwaukee Wisconsin
United States ImClone Investigational Site Mineola New York
United States ImClone Investigational Site Minneapolis Minnesota
United States ImClone Investigational Site Montebello California
United States ImClone Investigational Site Naperville Illinois
United States ImClone Investigational Site Nashville Tennessee
United States ImClone Investigational Site New Haven Connecticut
United States ImClone Investigational Site New London Connecticut
United States ImClone Investigational Site New Port Richey Florida
United States ImClone Investigational Site New York New York
United States ImClone Investigational Site Newark Ohio
United States ImClone Investigational Site Newport News Virginia
United States ImClone Investigational Site Norwich Connecticut
United States ImClone Investigational Site Ogden Utah
United States ImClone Investigational Site Oklahoma City Oklahoma
United States ImClone Investigational Site Orange California
United States ImClone Investigational Site Orlando Florida
United States ImClone Investigational Site Overland Park Kansas
United States ImClone Investigational Site Palm Springs California
United States ImClone Investigational Site Philadelphia Pennsylvania
United States ImClone Investigational Site Philadelphia Pennsylvania
United States ImClone Investigational Site Philadelphia Pennsylvania
United States ImClone Investigational Site Pine Bluff Arkansas
United States ImClone Investigational Site Pittsburgh Pennsylvania
United States ImClone Investigational Site Plano Texas
United States ImClone Investigational Site Port St. Lucie Florida
United States ImClone Investigational Site Raleigh North Carolina
United States ImClone Investigational Site Rancho Mirage California
United States ImClone Investigational Site Rexford New York
United States ImClone Investigational Site Richmond Kentucky
United States ImClone Investigational Site Richmond Virginia
United States ImClone Investigational Site Robbinsdale Minnesota
United States ImClone Investigational Site Rolla Missouri
United States ImClone Investigational Site San Diego California
United States ImClone Investigational Site Savannah Georgia
United States ImClone Investigational Site Seattle Washington
United States ImClone Investigational Site Shreveport Louisiana
United States ImClone Investigational Site South Bend Indiana
United States ImClone Investigational Site Southfield Michigan
United States ImClone Investigational Site Spokane Washington
United States ImClone Investigational Site Spokane Washington
United States ImClone Investigational Site St. Louis Missouri
United States ImClone Investigational Site St. Louis Park Minnesota
United States ImClone Investigational Site Stamford Connecticut
United States ImClone Investigational Site Stockton California
United States ImClone Investigational Site Stony Brook New York
United States ImClone Investigational Site Temple Texas
United States ImClone Investigational Site Trenton New Jersey
United States ImClone Investigational Site Tucker Georgia
United States ImClone Investigational Site Tucson Arizona
United States ImClone Investigational Site Valhalla New York
United States ImClone Investigational Site Vallejo California
United States ImClone Investigational Site Voorhees New Jersey
United States ImClone Investigational Site Walla Walla Washington
United States ImClone Investigational Site Winston-Salem North Carolina
United States ImClone Investigational Site Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
ImClone LLC Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Czech Republic,  Finland,  France,  Germany,  Hong Kong,  Italy,  Netherlands,  Norway,  Portugal,  Slovakia,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival Every 3 months after subject off-treatment No
Secondary Progression Free Survival Q6 Weeks No
Secondary Response Q6 Weeks No
Secondary Duration of Response Q6 Weeks No
Secondary Time to Response Q6 Weeks No
Secondary Disease Control Rate Q6 Weeks No
Secondary Safety Q3 Weeks Yes
Secondary Quality of Life Q6 Weeks No
Secondary Health Economics Q3 Weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A